IFNA17 and hepatocellular carcinoma: Recent studies have confirmed that IFN-α treatment can recruit the cytotoxic T cells in murine HCC models by remodeling glucose metabolism, as well as promote the infiltration of cytotoxic CD169 + macrophages and M1-like macrophages, and that combined treatment with ICIs or sorafenib has synergistic anti-tumor efficacy [212–214].